Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.

ABSTRACT: Coronavirus disease 2019 (COVID-19) is an infectious disease, caused by a newly emerged highly pathogenic virus called novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Targeting the main protease (M^pro, 3CL^pro) of SARS-CoV-2 is an appealing approach for drug development because this enzyme plays a significant role in the viral replication and transcription. The available crystal structures of SARS-CoV-2 M^pro determined in the presence of different ligands and inhibitor-like compounds provide a platform for the quick development of selective inhibitors of SARS-CoV-2 M^pro. In this study, we utilized the structural information of co-crystallized SARS-CoV-2 M^pro for the structure-guided drug discovery of high-affinity in

SUBMITTER: Mohammad T 

PROVIDER: S-EPMC7380256 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature